China’s Research on COVID-19
No.5: Chinese Medicine
28 July, 2020
Chinese medicine is one of China’s novel contributions to combat COVID-19. Over thousands of years, China has refined and recorded many prescriptions and medicines for curing diseases and saving lives including “Treatise on Febrile and Miscellaneous Diseases” and “Treatise on the Plague”.
Since the outbreak of COVID-19, Chinese medicine has been used in clinical trials. As of July 10, there are 142 Chinese medicine trials among 682 clinical trials in China. Chinese scholars published 1400 papers in academic journals on the treatment of COVID-19 using Chinese medicine. In January 2020, Chinese medicine was incorporated into the national “COVID-19 Infectious Pneumonia Diagnosis Program”.
In the study by YANG Ruozhong ’s group published in Pharmacological Research titled “Chemical Composition and Pharmacological Mechanism of Qing Fei Pai Du Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In Silico and experimental study”, a total of 129 compounds of Qingfei Paidu decoction were identified. The discovery explains the material basis and pharmacological action of Qingfei Paidu decoction, supporting the compatibility of Chinese medicine theory and its curative effects for COVID-19 pneumonia.
NI Li’s group published a paper titled "Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID-19" in Frontiers of Medicine, describing the identification, diagnosis, clinical and treatment process of three cases from a single family. Through the comparison of data, it is concluded that the combination of Chinese and Western medicine has a significant treatment effect.
Chinese medicine has a long history with practical innovation and generational lineage. There are many opportunities and challenges ahead on how to better serve the people’s health.